Merck’s ‘COVID Pill’ Shows Promise, But Mortality Benefits Will Be Hard To Prove
Accurate Viral Test Shows Drug’s Promise
Executive Summary
Early results from its novel antiviral are encouraging, but demonstrating life-saving qualities in a short window of time will be tricky.
You may also be interested in...
Natco Tests Compassionate Use Window In India For Merck’s COVID Pill
Natco seeks emergency approval in India for investigational therapy molnupiravir, currently being developed by Merck & Co for the treatment of non-hospitalized COVID-19 patients. The firm has linked its request to compassionate use amid a ferocious surge in COVID-19 cases in India, posing a potentially delicate choice for the regulator.
Merck’s COVID-19 Therapeutic Development Path Gets A Little Harder
After backing off of MRK-7110 for hospitalized patients the company’s focus is on the oral antiviral molnupiravir for outpatients – which would be a huge win, but the drug has yet to fully prove itself in the clinic.
Quick Listen: Scrip’s Five Must-Know Things
In this week's podcast version of Five Must-Know Things, hear about Roche's deal-making in a pandemic, coronavirus vaccine disinformation, Amgen’s Five Prime acquisition, a Novartis clinical trial failure, and new data for a Merck antiviral for the coronavirus.